{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:12:43Z","timestamp":1780686763748,"version":"3.54.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of traditional protein-targeted cancer therapies is a slow and arduous process, often taking years or even decades. In contrast, RNA-based therapies targeting crucial microRNA (miRNA) offer a faster alternative due to the sequence-specific nature of miRNA inhibitor binding. This, combined with the capacity of individual miRNA to influence multiple cellular pathways, makes these small RNA attractive targets for cancer therapy. While miRNA are known to be dysregulated in prostate cancer (PCa), identifying their individual contributions to disease progression and the identification of therapeutically actionable miRNA targets in PCa has been challenging due to limited profiling and lack of screening tools. To address this need, we developed miRKOv2, a miRNA-only CRISPR knockout library enabling systematic, genome-wide loss-of-function screens to identify miRNA essential for PCa cell survival. Our screens uncovered 70 potential essential miRNA candidates, with miR-483 demonstrating the most significant impact on PCa cell viability. Functional characterization revealed that miR-483 disruption potentiated apoptosis in PCa cell lines. Mechanistically, we uncovered a novel regulatory axis wherein miR-483-3p directly modulates a BCLAF1\/PUMA\/BAK1 apoptotic signaling network, highlighting its critical role in maintaining PCa cell survival. Our findings provide novel insights into the complex regulatory role of miRNA in PCa progression and offer a potential therapeutic strategy for targeting miRNA-mediated pathways in metastatic disease.<\/jats:p>","DOI":"10.1038\/s41419-025-08098-7","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:52:44Z","timestamp":1761321164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A microRNA CRISPR screen reveals microRNA-483-3p as an apoptotic regulator in prostate cancer cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Jonathan Tak-Sum","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6913-0809","authenticated-orcid":false,"given":"Ayeisha","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K. C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia A.","family":"Grigore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman J.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong Yeop","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino Marco","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-658X","authenticated-orcid":false,"given":"Leonardo","family":"Salmena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"8098_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8098_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Prim. 2021;7:9.","journal-title":"Nat Rev Dis Prim"},{"key":"8098_CR3","doi-asserted-by":"publisher","first-page":"e390166","DOI":"10.1200\/EDBK_390166","volume":"43","author":"AA Hamid","year":"2023","unstructured":"Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166 May.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"8098_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334. Sep.","journal-title":"Ann Oncol"},{"key":"8098_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","volume":"20","author":"LFR Gebert","year":"2019","unstructured":"Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20:21\u201337. Jan.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8098_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1101\/gr.082701.108","volume":"19","author":"RC Friedman","year":"2009","unstructured":"Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92\u2013105. Jan.","journal-title":"Genome Res"},{"key":"8098_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861\u201374. Nov 18.","journal-title":"Nat Rev Genet"},{"key":"8098_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrg.2016.134","volume":"17","author":"CP Bracken","year":"2016","unstructured":"Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17:719\u201332. Dec.","journal-title":"Nat Rev Genet"},{"key":"8098_CR9","doi-asserted-by":"crossref","unstructured":"Seyhan AA. Trials and tribulations of microRNA therapeutics. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25031469"},{"key":"8098_CR10","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1158\/0008-5472.CAN-08-0144","volume":"68","author":"S Ambs","year":"2008","unstructured":"Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162\u201370. Aug 1.","journal-title":"Cancer Res"},{"key":"8098_CR11","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.2353\/ajpath.2006.060480","volume":"169","author":"S Chiosea","year":"2006","unstructured":"Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, et al. Up-regulation of dicer, a component of the microRNA machinery, in prostate adenocarcinoma. Am J Pathol. 2006;169:1812\u201320. Nov.","journal-title":"Am J Pathol"},{"key":"8098_CR12","doi-asserted-by":"publisher","first-page":"ra29","DOI":"10.1126\/scisignal.2000594","volume":"3","author":"L Poliseno","year":"2010","unstructured":"Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b\u2009~\u200925 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3:ra29 Apr 13.","journal-title":"Sci Signal"},{"key":"8098_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/0008-5472.CAN-16-2529","volume":"77","author":"R Das","year":"2017","unstructured":"Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Res. 2017;77:1021\u201334. Feb 15.","journal-title":"Cancer Res"},{"key":"8098_CR14","doi-asserted-by":"publisher","first-page":"e4029","DOI":"10.1371\/journal.pone.0004029","volume":"3","author":"N Mercatelli","year":"2008","unstructured":"Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE. 2008;3:e4029 Dec 24.","journal-title":"PLoS ONE"},{"key":"8098_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2020.05.215","volume":"529","author":"K Kim","year":"2020","unstructured":"Kim K, Kim HH, Lee C-H, Kim S, Cheon GJ, Kang KW, et al. Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer. Biochem Biophys Res Commun. 2020;529:707\u201313. Aug 27.","journal-title":"Biochem Biophys Res Commun"},{"key":"8098_CR16","doi-asserted-by":"crossref","unstructured":"Gabra M, Pastrello C, Machado N, Chow JT-S, Kotlyar M, Tokar T, et al. Essential gene networks in acute myeloid leukemia identified using a microRNA -knockout CRISPR library screen. BioRxiv. 2019;","DOI":"10.1101\/661140"},{"key":"8098_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.canlet.2021.07.045","volume":"520","author":"KJ Campbell","year":"2021","unstructured":"Campbell KJ, Leung HY. Evasion of cell death: a contributory factor in prostate cancer development and treatment resistance. Cancer Lett. 2021;520:213\u201321. Nov 1.","journal-title":"Cancer Lett"},{"key":"8098_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jcb.20634","volume":"97","author":"S McKenzie","year":"2006","unstructured":"McKenzie S, Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem. 2006;97:18\u201332. Jan 1.","journal-title":"J Cell Biochem"},{"key":"8098_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184\u201391. Feb.","journal-title":"Nat Biotechnol"},{"key":"8098_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep22312","volume":"6","author":"H Chang","year":"2016","unstructured":"Chang H, Yi B, Ma R, Zhang X, Zhao H. Xi Y. CRISPR\/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Sci Rep. 2016;6:22312. Feb 29.","journal-title":"Sci Rep"},{"key":"8098_CR21","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1534\/g3.117.041277","volume":"7","author":"T Hart","year":"2017","unstructured":"Hart T, Tong AHY, Chan K, Van Leeuwen J, Seetharaman A, Aregger M, et al. Evaluation and design of genome-wide CRISPR\/SpCas9 knockout screens. G3. 2017;7:2719\u201327. Aug 7.","journal-title":"G3"},{"key":"8098_CR22","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","volume":"163","author":"T Hart","year":"2015","unstructured":"Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 2015;163:1515\u201326. Dec 3.","journal-title":"Cell"},{"key":"8098_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.15252\/msb.20145216","volume":"10","author":"T Hart","year":"2014","unstructured":"Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol. 2014;10:733 Jul 1.","journal-title":"Mol Syst Biol"},{"key":"8098_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01341-4","volume":"16","author":"DJ Merk","year":"2024","unstructured":"Merk DJ, Paul L, Tsiami F, Hohenthanner H, Kouchesfahani GM, Haeusser LA, et al. CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines. Genome Med. 2024;16:82. Jun 17.","journal-title":"Genome Med"},{"key":"8098_CR25","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1261\/rna.066282.118","volume":"24","author":"JS Kurata","year":"2018","unstructured":"Kurata JS, Lin R-J. MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA. 2018;24:966\u201381. Jul.","journal-title":"RNA"},{"key":"8098_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-016-1015-8","volume":"17","author":"T Hart","year":"2016","unstructured":"Hart T, Moffat J. BAGEL: a computational framework for identifying essential genes from pooled library screens. BMC Bioinforma. 2016;17:164. Apr 16.","journal-title":"BMC Bioinforma"},{"key":"8098_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/carcin\/18.6.1215","volume":"18","author":"D Bello","year":"1997","unstructured":"Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen-responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis. 1997;18:1215\u201323. Jun.","journal-title":"Carcinogenesis"},{"key":"8098_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1530\/ERC-22-0108","volume":"29","author":"K Kukkonen","year":"2022","unstructured":"Kukkonen K, Autio-Kimura B, Rauhala H, Kesseli J, Nykter M, Latonen L, et al. Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen. Endocr Relat Cancer. 2022;29:717\u201333. Dec 1.","journal-title":"Endocr Relat Cancer"},{"key":"8098_CR29","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168 Dec 16.","journal-title":"Nucleic Acids Res"},{"key":"8098_CR30","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1101\/gr.2722704","volume":"14","author":"A Rodriguez","year":"2004","unstructured":"Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14:1902\u201310. Oct.","journal-title":"Genome Res"},{"key":"8098_CR31","doi-asserted-by":"crossref","unstructured":"S\u00e9l\u00e9nou C, Brioude F, Giabicani E, Sobrier M-L, Netchine I. IGF2: development, genetic and epigenetic abnormalities. Cells. 2022;11.","DOI":"10.3390\/cells11121886"},{"key":"8098_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330. Jan 1.","journal-title":"Nucleic Acids Res"},{"key":"8098_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.19","volume":"4","author":"I Kuperstein","year":"2015","unstructured":"Kuperstein I, Bonnet E, Nguyen HA, Cohen D, Viara E, Grieco L, et al. Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps. Oncogenesis. 2015;4:e160. Jul 20.","journal-title":"Oncogenesis"},{"key":"8098_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.cellbio.15.1.269","volume":"15","author":"I Budihardjo","year":"1999","unstructured":"Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269\u201390.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"8098_CR35","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1158\/0008-5472.CAN-09-4456","volume":"70","author":"A Veronese","year":"2010","unstructured":"Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, et al. Oncogenic role of miR-483-3p at the IGF2\/483 locus. Cancer Res. 2010;70:3140\u20139. Apr 15.","journal-title":"Cancer Res"},{"key":"8098_CR36","doi-asserted-by":"publisher","first-page":"31361","DOI":"10.18632\/oncotarget.8913","volume":"7","author":"L Lupini","year":"2016","unstructured":"Lupini L, Pepe F, Ferracin M, Braconi C, Callegari E, Pagotto S, et al. Over-expression of the miR-483-3p overcomes the miR-145\/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget. 2016;7:31361\u201371. May 24.","journal-title":"Oncotarget"},{"key":"8098_CR37","first-page":"490","volume":"11","author":"K Wu","year":"2018","unstructured":"Wu K, Wang J, He J, Chen Q, Yang L. miR-483-3p promotes proliferation and migration of neuroblastoma cells by targeting PUMA. Int J Clin Exp Pathol. 2018;11:490\u2013501. Feb 1.","journal-title":"Int J Clin Exp Pathol"},{"key":"8098_CR38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/1093526619873491","volume":"23","author":"G Che","year":"2020","unstructured":"Che G, Gao H, Tian J, Hu Q, Xie H, Zhang Y. MicroRNA-483-3p promotes proliferation, migration, and invasion and induces chemoresistance of Wilms\u2019 tumor cells. Pediatr Dev Pathol. 2020;23:144\u201351.","journal-title":"Pediatr Dev Pathol"},{"key":"8098_CR39","doi-asserted-by":"publisher","first-page":"D360","DOI":"10.1093\/nar\/gkx1144","volume":"46","author":"T Tokar","year":"2018","unstructured":"Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild A-C, Tsay M, et al. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. 2018;46:D360\u201370. Jan 4.","journal-title":"Nucleic Acids Res"},{"key":"8098_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/cdd.2017.179","volume":"25","author":"H Kalkavan","year":"2018","unstructured":"Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018;25:46\u201355. Jan.","journal-title":"Cell Death Differ"},{"key":"8098_CR41","doi-asserted-by":"crossref","unstructured":"King LE, Hohorst L, Garc\u00eda-S\u00e1ez AJ. Expanding roles of BCL-2 proteins in apoptosis execution and beyond. J Cell Sci. 2023;136.","DOI":"10.1242\/jcs.260790"},{"key":"8098_CR42","doi-asserted-by":"publisher","first-page":"11399","DOI":"10.18632\/oncotarget.2550","volume":"5","author":"H Tamaki","year":"2014","unstructured":"Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, et al. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Oncotarget. 2014;5:11399\u2013412. Nov 30.","journal-title":"Oncotarget"},{"key":"8098_CR43","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1038\/onc.2009.42","volume":"27","author":"JD Pi\u00f1on","year":"2008","unstructured":"Pi\u00f1on JD, Labi V, Egle A, Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene. 2008;27:S41\u201352. Dec.","journal-title":"Oncogene"},{"key":"8098_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium.","year":"2012","unstructured":"ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57\u201374. Sep 6.","journal-title":"Nature"},{"key":"8098_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3892\/ol.2021.13176","volume":"23","author":"Z Yu","year":"2022","unstructured":"Yu Z, Zhu J, Wang H, Li H, Jin X. Function of BCLAF1 in human disease. Oncol Lett. 2022;23:58 Feb.","journal-title":"Oncol Lett"},{"key":"8098_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4939-6588-5_3","volume":"1521","author":"J Yoo","year":"2017","unstructured":"Yoo J, Hajjar RJ, Jeong D. Generation of efficient miRNA inhibitors using tough decoy constructs. Methods Mol Biol. 2017;1521:41\u201353.","journal-title":"Methods Mol Biol"},{"key":"8098_CR47","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1093\/nar\/gkp040","volume":"37","author":"T Haraguchi","year":"2009","unstructured":"Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009;37:e43 Apr.","journal-title":"Nucleic Acids Res"},{"key":"8098_CR48","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343. Jul 5.","journal-title":"Nucleic Acids Res"},{"key":"8098_CR49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313. Sep 25.","journal-title":"Comput Struct Biotechnol J"},{"key":"8098_CR50","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41596-018-0113-7","volume":"14","author":"B Wang","year":"2019","unstructured":"Wang B, Wang M, Zhang W, Xiao T, Chen C-H, Wu A, et al. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat Protoc. 2019;14:756\u201380. Mar.","journal-title":"Nat Protoc"},{"key":"8098_CR51","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nbt.3567","volume":"34","author":"DW Morgens","year":"2016","unstructured":"Morgens DW, Deans RM, Li A, Bassik MC. Systematic comparison of CRISPR\/Cas9 and RNAi screens for essential genes. Nat Biotechnol. 2016;34:634\u20136. Jun.","journal-title":"Nat Biotechnol"},{"key":"8098_CR52","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1590\/s1677-5538.ibju.2016.0595","volume":"43","author":"Z-G Yang","year":"2017","unstructured":"Yang Z-G, Ma X-D, He Z-H, Guo Y-X. miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5. Int Braz J Urol. 2017;43:1060\u20137.","journal-title":"Int Braz J Urol"},{"key":"8098_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.molcel.2008.08.008","volume":"32","author":"S Bonnal","year":"2008","unstructured":"Bonnal S, Mart\u00ednez C, F\u00f6rch P, Bachi A, Wilm M, Valc\u00e1rcel J. RBM5\/Luca-15\/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell. 2008;32:81\u201395. Oct 10.","journal-title":"Mol Cell"},{"key":"8098_CR54","doi-asserted-by":"publisher","first-page":"15708","DOI":"10.1073\/pnas.0805569105","volume":"105","author":"K Fushimi","year":"2008","unstructured":"Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY. Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci USA. 2008;105:15708\u201313. Oct 14.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8098_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1073-x","volume":"20","author":"L Fan","year":"2020","unstructured":"Fan L, Li H, Zhang Y. LINC00908 negatively regulates microRNA-483-5p to increase TSPYL5 expression and inhibit the development of prostate cancer. Cancer Cell Int. 2020;20:10. Jan 9.","journal-title":"Cancer Cell Int"},{"key":"8098_CR56","doi-asserted-by":"publisher","first-page":"114750","DOI":"10.1016\/j.celrep.2024.114750","volume":"43","author":"I Sandovici","year":"2024","unstructured":"Sandovici I, Fernandez-Twinn DS, Campbell N, Cooper WN, Sekita Y, Zvetkova I, et al. Overexpression of Igf2-derived Mir483 inhibits Igf1 expression and leads to developmental growth restriction and metabolic dysfunction in mice. Cell Rep. 2024;43:114750 Sep 24.","journal-title":"Cell Rep"},{"key":"8098_CR57","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1200\/JCO.2023.41.6_suppl.182","volume":"41","author":"S Perimbeti","year":"2023","unstructured":"Perimbeti S, Jamroze A, Attwood K, Farmer B, Beumer JH, Bies R, et al. Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC). JCO. 2023;41:182\u2013182. Feb 20.","journal-title":"JCO"},{"key":"8098_CR58","doi-asserted-by":"publisher","first-page":"e100806","DOI":"10.1371\/journal.pone.0100806","volume":"9","author":"AS Afshar","year":"2014","unstructured":"Afshar AS, Xu J, Goutsias J. Integrative identification of deregulated miRNA\/TF-mediated gene regulatory loops and networks in prostate cancer. PLoS ONE. 2014;9:e100806 Jun 26.","journal-title":"PLoS ONE"},{"key":"8098_CR59","doi-asserted-by":"crossref","unstructured":"Oh-Hohenhorst SJ, Lange T. Role of metastasis-related microRNAs in prostate cancer progression and treatment. Cancers. 2021;13.","DOI":"10.3390\/cancers13174492"},{"key":"8098_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137. Jan 3.","journal-title":"Science"},{"key":"8098_CR61","doi-asserted-by":"publisher","first-page":"D68","DOI":"10.1093\/nar\/gkt1181","volume":"42","author":"A Kozomara","year":"2014","unstructured":"Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:D68\u201373. Jan(Database issue).","journal-title":"Nucleic Acids Res"},{"key":"8098_CR62","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.aac7041","volume":"350","author":"T Wang","year":"2015","unstructured":"Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, et al. Identification and characterization of essential genes in the human genome. Science. 2015;350:1096\u2013101. Nov 27.","journal-title":"Science"},{"key":"8098_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15178","volume":"8","author":"DW Morgens","year":"2017","unstructured":"Morgens DW, Wainberg M, Boyle EA, Ursu O, Araya CL, Tsui CK, et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens. Nat Commun. 2017;8:15178. May 5.","journal-title":"Nat Commun"},{"key":"8098_CR64","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357\u20139. Mar 4.","journal-title":"Nat Methods"},{"key":"8098_CR65","doi-asserted-by":"publisher","first-page":"W148","DOI":"10.1093\/nar\/gkad283","volume":"51","author":"S Tastsoglou","year":"2023","unstructured":"Tastsoglou S, Alexiou A, Karagkouni D, Skoufos G, Zacharopoulou E, Hatzigeorgiou AG. DIANA-microT 2023: including predicted targets of virally encoded miRNAs. Nucleic Acids Res. 2023;51:W148\u201353. Jul 5.","journal-title":"Nucleic Acids Res"},{"key":"8098_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.171","volume":"3","author":"A Perelman","year":"2012","unstructured":"Perelman A, Wachtel C, Cohen M, Haupt S, Shapiro H, Tzur A. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis. 2012;3:e430. Nov 22.","journal-title":"Cell Death Dis"},{"key":"8098_CR67","doi-asserted-by":"publisher","first-page":"110180","DOI":"10.1016\/j.isci.2024.110180","volume":"27","author":"E Sellars","year":"2024","unstructured":"Sellars E, Savguira M, Wu J, Cancelliere S, Jen M, Krishnan R, et al. A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity. iScience. 2024;27:110180 Jul 19.","journal-title":"iScience"},{"key":"8098_CR68","doi-asserted-by":"publisher","first-page":"e1006752","DOI":"10.1371\/journal.pcbi.1006752","volume":"15","author":"A Malyutina","year":"2019","unstructured":"Malyutina A, Majumder MM, Wang W, Pessia A, Heckman CA, Tang J. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput Biol. 2019;15:e1006752 May 20.","journal-title":"PLoS Comput Biol"},{"key":"8098_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-021-05445-7","volume":"14","author":"P M\u00e4kel\u00e4","year":"2021","unstructured":"M\u00e4kel\u00e4 P, Zhang SM, Rudd SG. Drug synergy scoring using minimal dose response matrices. BMC Res Notes. 2021;14:27. Jan 19.","journal-title":"BMC Res Notes"},{"key":"8098_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17:10 May 2.","journal-title":"EMBnet J"},{"key":"8098_CR71","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754\u201360. Jul 15.","journal-title":"Bioinformatics"},{"key":"8098_CR72","doi-asserted-by":"publisher","first-page":"D663","DOI":"10.1093\/nar\/gkad1027","volume":"52","author":"C Pastrello","year":"2024","unstructured":"Pastrello C, Kotlyar M, Abovsky M, Lu R, Jurisica I. PathDIP 5: improving coverage and making enrichment analysis more biologically meaningful. Nucleic Acids Res. 2024;52:D663\u201371. Jan 5.","journal-title":"Nucleic Acids Res"},{"key":"8098_CR73","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350. Oct 25.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8098_CR74","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373. Jul.","journal-title":"Nat Genet"},{"key":"8098_CR75","doi-asserted-by":"crossref","unstructured":"Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG, et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database. 2016;2016.","DOI":"10.1093\/database\/baw100"},{"key":"8098_CR76","doi-asserted-by":"publisher","first-page":"D157","DOI":"10.1093\/nar\/gks1233","volume":"41","author":"R Dreos","year":"2013","unstructured":"Dreos R, Ambrosini G, Cavin P\u00e9rier R, Bucher P. EPD and EPD new, high-quality promoter resources in the next-generation sequencing era. Nucleic Acids Res. 2013;41:D157\u201364. Jan(Database issue).","journal-title":"Nucleic Acids Res"},{"key":"8098_CR77","doi-asserted-by":"publisher","first-page":"D1082","DOI":"10.1093\/nar\/gkad987","volume":"52","author":"BJ Raney","year":"2024","unstructured":"Raney BJ, Barber GP, Benet-Pag\u00e8s A, Casper J, Clawson H, Cline MS, et al. The UCSC Genome Browser database: 2024 update. Nucleic Acids Res. 2024;52:D1082\u20138. Jan 5.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08098-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:03:17Z","timestamp":1761321797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8098"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08098-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study uses data from publicly available datasets where informed consent was obtained and does not require IRB review. This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"752"}}